Evidence map›Paper›PMID 25779225›Full record

ArticleEpilepsia2015

The anticonvulsant retigabine is a subtype selective modulator of GABAA receptors.

Marco Treven, Xaver Koenig, Elham Assadpour, Enkhbileg Gantumur, Christiane Meyer, Karlheinz Hilber, Stefan Boehm, Helmut Kubista

Open access · hybridAbstract read
In one paragraph

Article in Epilepsia, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 31 papers.

0numbers the graph read from it
0cells of the map it votes in
31citing papers in PubMed
2.1field-weighted citation impact, top 14% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

31 citing papers in PubMed, 47 citations in OpenAlex.

  1. Article
  2. Review
  3. Review
  4. Article
  5. Review
  6. Article
  7. KAddiction biology · 2024
    Article
  8. Glial KCNQ KNeuron · 2024
    Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. The KNeuroscience · 2021
    Article
  15. Chemical modulation of Kv7 potassium channels.RSC medicinal chemistry · 2021
    Review
  16. Article
  17. Article
  18. Review
  19. Pharmacological Manipulation of KFrontiers in physiology · 2020
    Review
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 1 institution in 1 country.

Marco TrevenDepartment of Neurophysiology and Neuropharmacology, Center for Physiology and Pharmacology, Medical University of Vienna, Vienna, Austria.
Xaver Koenig
Elham Assadpour
Enkhbileg Gantumur
Christiane Meyer
Karlheinz Hilber
Stefan Boehm
Helmut Kubista
Medical University of Vienna · AT

Funding

Austrian Science Fund FWF P 23658Austrian Science Fund FWF W 1205
6 · The paper itself

Abstract

objectiveWithin its range of therapeutic plasma concentrations, the anticonvulsant retigabine (ezogabine) is believed to selectively act on Kv7 channels. Here, the contribution of specific γ-aminobutyric acid (GABA)A receptor subtypes to the antiseizure effects of retigabine was investigated.

methodsUsing patch-clamp recordings, seizure-like activity, tonic currents, and GABA-induced currents in hippocampal neurons were tested for their sensitivity toward retigabine, as were recombinant GABAA receptors expressed in tsA 201 cells.

resultsRetigabine reduced seizure-like activity elicited by low Mg(2+) in a concentration-dependent manner with half maximal inhibition at 1 μm. Seizure-like activity triggered by blocking either Kv7 channels or GABAA receptors was equally reduced by retigabine, but when these channels/receptors were blocked simultaneously, the inhibition was lost. Retigabine (10 μm) enhanced bicuculline-sensitive tonic currents in hippocampal neurons, but failed to affect GABA-evoked currents. However, when receptors involved in phasic GABAergic inhibition were blocked by penicillin, retigabine did enhance GABA-evoked currents. In tsA 201 cells expressing various combinations of GABAA receptor subunits, 10 μm retigabine enhanced currents through α1β2δ, α4β2δ, α4β3δ, and α6β2δ receptors, but left currents through α1β2γ2S, α4β3γ2S, α5β3γ2S, and α6β2γ2S receptors unaltered. With αβ receptors, retigabine diminished currents through α1β2 and α4β3, but increased currents through α6β2 receptors. The enhancement of currents through α1β2δ receptors by retigabine was concentration dependent and became significant at 1 μm. SIGNIFICANCE: These results demonstrate that retigabine is a subtype selective modulator of GABAA receptors with preference for extrasynaptic δ-containing receptors; this property may contribute to its broad antiepileptic effectiveness and explain its lack of effect on absence seizures.

Indexed as

AnimalsAnticonvulsantsCarbamatesCells, CulturedDose-Response Relationship, DrugGABA ModulatorsHippocampusPhenylenediaminesRatsRats, Sprague-DawleyReceptors, GABA-ASeizuresAnticonvulsantsCarbamatesezogabineGABA ModulatorsPhenylenediaminesReceptors, GABA-AExtrasynaptic GABAA receptorsKv7 channelsRetigabineSeizure-like activity

Identifiers

PMID25779225
PMCPMC4949651
OpenAlexW2051920240

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.